PROGRAMS - Overview
Today more than 70 million American adults are suffering from psychiatric and neurodegenerative diseases. Despite the significant unmet medical need for drugs with improved efficacy and reduced side effects, the current pipeline of new agents is very limited. Furthermore, in the last 40 years, few new effective targets or breakthrough therapeutic approaches for treating psychiatric and neurological disorders have been identified.
We are taking a new, functional approach focused on directly targeting alterations in synaptic transmission in CNS disease to discover new classes of therapies that address the fundamental, underlying disease biology.